FindTrial
Sign In

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day

Status
TEMPORARILY_NOT_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00596115
Enrollment
Unknown
Registered
2008-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2012-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Interventions

DRUGR(+) pramipexole dihydrochloride monohydrate

20 mg tid per day orally

Sponsors

University of Pittsburgh
CollaboratorOTHER
University of Nebraska
CollaboratorOTHER
Bennett, James P., Jr., M.D., Ph.D.
Lead SponsorINDIV

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years

Inclusion criteria

* Definite diagnosis of ALS

Exclusion criteria

* No prior participation in R(+)PPX clinical studies

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026